Subscribe to receive our Floor Reports covering all the action on the Texas House and Senate floor!
Relating to the administration and oversight of investigational adult stem cell treatments administered to certain patients.
According to the Legislative Budget Board, no fiscal impact to the state is anticipated.
HB 3148 would require the Department of State Health Services (DSHS) to establish and maintain an investigational stem cell registry that lists each physician who administers an investigational stem cell treatment, as well as adopt a form for informed consent. It would also require an institutional review board that oversees investigational stem cell treatments to meet certain conditions.
Additionally, this bill would prohibit a governmental entity from interfering with an eligible patient's access to or use of an investigational stem cell treatment unless the treatment uses an adult stem cell product that is considered an adulterated or misbranded drug. It would also prohibit a governmental entity from considering the adult stem cell product to be an adulterated or misbranded drug solely on the basis that the U.S. Food and Drug Administration has not approved it.